Ruboxistaurin Reduced Vision Loss In Patients With Moderate To Severe Non-Proliferative Diabetic Retinopathy In A New (Medical News Today)
Eli Lilly and Company (NYSE: LLY) today announced results from a three-year phase 3 clinical trial in which ruboxistaurin mesylate (proposed brand name Arxxant(TM), pronounced ark-ZONT) reduced the risk of sustained moderate vision loss by 40 percent when compared to placebo in patients with moderate to severe non-proliferative diabetic retinopathy (DR). [click link for full article]

FDA plans tougher review of devices (Boston Globe)
WASHINGTON -- The Food and Drug Administration yesterday outlined a plan for tougher monitoring of the safety of medical devices once the products are on the market. It comes just after Democrats , who promise more aggressive oversight of the FDA, wrested control from Republicans in the House of Representatives and Senate.